Nexalin Technology (NXL) EBT Margin Growth (1y) (2022 - 2026)
Nexalin Technology (NXL) EBT Margin Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -719.00 |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 687.00 |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 458.00 |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 88.00 |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 374.00 |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 343.00 |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 84.00 |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | -126.00 |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 165.00 |
| 10 | Nexalin Technology | 7.01 Mn | 6.00 Mn | 8,897.00 | -1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.62 Mn |
| Mar 31, 2026 | -918,039.00 |
| Dec 31, 2025 | 902,483.00 |
| Sep 30, 2025 | -574,705.00 |
| Jun 30, 2025 | 254,119.00 |
| Mar 31, 2025 | -351,449.00 |
| Dec 31, 2024 | -660,592.00 |
| Sep 30, 2024 | 273,146.00 |
| Jun 30, 2024 | -246,681.00 |
| Mar 31, 2024 | 111,822.00 |
| Dec 31, 2023 | -182,713.00 |
| Sep 30, 2023 | -947,108.00 |
| Jun 30, 2023 | -220,547.00 |
| Mar 31, 2023 | -232,737.00 |
| Dec 31, 2022 | 50,881.00 |
| Sep 30, 2022 | 320,075.00 |